Biomarin Pharmaceutical Inc

NASDAQ: BMRN
$66.20
+$0.16 (+0.2%)
Real Time Data Delayed 15 Min.

BMRN Articles

Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of the other top players in the health care sector.
In a new research report, Baird notes two biotech companies in its research coverage universe that may be considered speculative takeover targets, and a third is a possible target as well.
Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that way.
A new JPMorgan research report says it time to buy the health care sector and sell consumer staples, which have run hard this year.
Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.
With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls by the week's end.
Typically each year, the first quarter is the slowest for biotech stocks. SunTrust Robinson Humphrey has four stocks rated Buy that should come in fine when numbers are released.
BioMarin Pharmaceutical is ready to break above the $1 billion revenue barrier in 2016, a feat that marks a major hurdle for many biotech and emerging pharmaceutical companies.
Jefferies believes most of the significant biotech downside already occurred, though volatility could continue in the near term.
BioMarin Pharmaceutical made waves early Monday following the release of late-stage results from its pegvaliase study.
A new research report from Jefferies focuses on a set of growth stocks for this week that have big upside. These four have some serious upside potential.
24/7 Wall St. has collected three big FDA decisions coming up in March and added some color, along with the trading range and price target.
With biotechs still way out of favor, investors need to be cautious, as often these companies are dependent on binary data. These three could have positive upcoming data presented.
The top analyst upgrades, downgrades and initiations seen on Monday, February 29, include Huntington Bancshares, Nucor, Orexigen Therapeutics, SanDisk, Square and VIVUS.
Investors really took to BioMarin Pharmaceuticals stock and there was a favorable jump after the fourth-quarter earnings report.